NEW: Prof Matteo Bertini’s comment on this edition of the ClinicalEVIDENCE newsletter:
Matteo Bertini, M.D, PhD, FAIAC
Professor of Cardiology, Head of EP lab, Cardiological Center, Sant’ Anna University Hospital
The impact of battery longevity is impressive!
This issue highlights terrific cost savings per person based on different battery longevity. Beyond cost savings, it’s crucial to stress the reduced risk of complications from replacements.
Considering these data & evidence on infection risks related to replacements, during first device implantation, especially CRT-D, battery longevity should be a key factor. This is a rare case where evidence-based clinical practice aligns perfectly with healthcare cost savings.
Delve into this newsletter to learn more.
Summary
This edition of Clinical Evidence offers an overview of extended CRT-D battery performance and benefit, provides an in-depth summary of the evidence supporting S-ICD journey and delve into the first data about the EMPOWER leadless pacemaker.
An economic analysis1 confirms the significant cost-saving associated with the use of extended battery longevity (2.1Ah) in CRT-D devices.
Key Takeaways
- CRT-D extended battery longevity and economic impact: Extended longevity CRT-D devices leads to minimizing replacements and enhances patient care cost-effectiveness. This data suggest long-term economic factors should be accounted for in device selection.¹
- A literature review supporting S-ICD as a valid alternative to TV-ICD: The S-ICD has emerged as a valid and safe alternative to the TV-ICD, reinforced by a decade of consolidated clinical evidence and continuous technological advancements.²
- New data on pacing performance of the EMPOWER : New data on pacing performance of the EMPOWER : New data from MODULAR ATP Trial demonstrated safety and efficacy on the pacing performance of the first Boston scientific leadless pacemaker.³
Gain deeper insights by downloading the full newsletter
